Reducing the Native Tropism of Adenovirus Vectors Requires Removal of both CAR and Integrin Interactions

DAVID A. EINFELD,* ROSANNA SCHROEDER, PETER W. ROELVINK, ALENA LIZONOVA, C. RICHTER KING, IMRE KOVESDI, AND THOMAS J. WICKHAM

GenVec, Inc., Gaithersburg, Maryland 20878

Received 19 April 2001/Accepted 21 August 2001

The development of tissue-selective virus-based vectors requires a better understanding of the role of receptors in gene transfer in vivo, both to rid the vectors of their native tropism and to introduce new specificity. CAR and αv integrins have been identified as the primary cell surface components that interact with adenovirus type 5 (Ad5)-based vectors during in vitro transduction. We have constructed a set of four vectors, which individually retain the wild-type cell interactions, lack CAR binding, lack αv integrin binding, or lack both CAR and αv integrin binding. These vectors have been used to examine the roles of CAR and αv integrin in determining the tropism of Ad vectors in a mouse model following intrajugular or intramuscular injection. CAR was found to play a significant role in liver transduction. The absence of CAR binding alone, however, had little effect on the low level of expression from Ad in other tissues. Binding of αv integrins appeared to have more influence than did binding of CAR in promoting the expression in these tissues and was also found to be important in liver transduction by Ad vectors. An effect of the penton base modification was a reduction in the number of vector genomes that could be detected in several tissues. In the liver, where CAR binding is important, combining defects in CAR and αv integrin binding was essential to effectively reduce the high level of expression from Ad vectors. While there may be differences in Ad vector tropism among species, our results indicate that both CAR and αv integrins can impact vector distribution in vivo. Disruption of both CAR and αv integrin interactions may be critical for effectively reducing native tropism and enhancing the efficacy of specific targeting ligands in redirecting Ad vectors to target tissues.

Adenoviruses (Ad) have been widely used for gene therapy applications because they can accommodate relatively large transgenes, be manufactured to high titer and purity, and transduce a relatively wide range of cells independent of their replicative state. Applications for Ad vectors have been limited by the native tropism of the virus, which restricts their ability to transduce some tissues of interest. In addition, the native tropism-dependent transduction of nontarget tissues may limit applications because of undesired side effects. Therefore, development of Ad vectors that could target specific tissues following systemic or minimally invasive administration would greatly enhance their therapeutic potential and expand their application.

Two interactions between Ad coat proteins and cell surface receptors have been identified as determinants of transduction by Ad vectors. The knob domain of the fiber protein binds to the CAR protein, and an RGD motif within a loop of the penton base protein binds to αv integrins. As a target for high-affinity binding by the fiber knob, the CAR protein plays a prominent role in transduction of cells in vitro (10, 11). This interaction is conserved among the majority of Ad serotypes (19). The murine homologue of CAR is highly conserved in sequence relative to the human protein and functions as a receptor for human Ad (4, 22). CAR is expressed in a broad range of human tissues, including heart, prostate, pancreas, brain, kidney, liver, and lung, while in mice CAR is expressed in similar tissues but its expression in the liver is more prominent (4, 7, 22). In mice the liver is the major tissue transduced following intravenous administration of Ad vectors and is also the site where fiber knobs accumulate when the soluble protein is injected into the bloodstream (33). On the other hand, absence of CAR expression on the surface of human airway epithelia may limit gene delivery to this tissue (24, 32). Nevertheless, the role of CAR in determining which tissues are transduced is not clear (7).

The interaction between penton base and αv integrins was identified for its role in promoting the internalization of virus after it attaches to the cell surface (27). Integrins direct Ad to clathrin-mediated endocytosis and may have additional functions in promoting escape from the endosome (14). The integrin interaction does not appear essential for Ad transduction in vitro (3). Nevertheless, some of the current limitations of Ad vectors in vivo have been attributed to absence or inappropriate distribution of αv integrin expression in the target tissue (8, 16).

We constructed a panel of four Ad vectors which bind CAR and integrins, bind CAR only, bind integrins only, or bind neither CAR nor integrins. These tropism-modified vectors are still capable of being produced to high titer in a specialized production cell line. The panel of vectors was used to examine the role of these interactions in determining the native tropism of Ad in an animal model. Our results indicate that the vector doubly ablated for both CAR and αv integrin binding represents the best candidate for a base vector that could be redirected by incorporation of specific targeting ligands.
Materials and Methods

Cells. A549, Ramos, and CHO cells were obtained from the American Type Culture Collection (Manassas, Va.) and cultured under standard conditions. 293-HA cells have been described previously (6). AE25 is an E1-complementing cell line derived from A549 cells. AE25-HA cells were obtained by Geneticin (Life Technologies, Gaithersburg, Md.) selection of AE25 cells following transduction with a retrovirus encoding a membrane-anchored single-chain antibody reactive with an influenza virus hemagglutinin epitope (HA) (6). The retrovirus stock was produced by transfection of RetroPackP676 cells (Clontech, Palo Alto, Calif.) with a plNCX-based plasmid (Clontech) expressing the anti-HA SFv.

Ad vector construction. AdL is an E1- and E3-deleted Ad5-based vector that carries the luciferase transgene in the E1 region under the control of the cytomegalovirus promoter. AdL.F* has a modified AB loop in fiber (R412S, A415G, A416G, and K417G) that abolishes CAR binding (20). In addition, AdL.F* has an insertion in the HI loop, between residues 543 and 544, of the sequence ATCATATGGATAA). As a result, the penton base protein in this construct has

\[
\text{CTCTTAACTGTGACCTTAAATGAGGGGTGTGCTAACTC}
\]

and then stored at

\[
\text{NheI fragment in E3. A}
\]

Vector genomes were excised from plasmids by digestion with the annealed primers SpeHAs (CTAGTTATCCATATGACCGCCTGGACCAACACATCCATGTGACCTGTCGACATGGATGATGATAA) and SpeHAa (CTAGAAGCATAATCTGGGAACGACGGTCTTGGTCCTGTGTACC). The modified fiber was then isolated as a Xhol-MstI fragment and cloned into pGEM3Z(E3)10X, which carries an XhoI site at the 3′ end of the genome minus the XhoI fragment in E3. A Drfl fragment from this plasmid was used to construct the complete vector genome of AdL.F* by recombination in Escherichia coli.

Replacement of the penton base RGD by an Spel linker has been described previously (26). To produce AdL.PB*F*, the HA epitope was inserted into this Spel site by ligation with the annealed primers SpeHAs (CTAGTTATCCATATGACCGCCTGGACCAACACATCCATGTGACCTGTCGACATGGATGATGATAA) and SpeHAa (CTAGAAGCATAATCTGGGAACGACGGTCTTGGTCCTGTGTACC). The modified fiber was then isolated as a Xhol-MstI fragment and cloned into pGEM3Z(E3)10X, which carries an XhoI site at the 3′ end of the genome minus the XhoI fragment in E3. A Drfl fragment from this plasmid was used to construct the complete vector genome of AdL.F* by recombination in Escherichia coli.

In vitro transduction assays. Transduction assays were performed on 10^5 cells. The cells were preincubated with purified fiber protein (5 μg/ml), purified penton base (100 μg/ml), a combination of the two, or medium alone for 60 min (18). The higher concentration of penton-base protein accompanies the 30-fold lower affinity of this interaction relative to fiber (27). Vector was then added at 50 particles per cell for AE25, AE25-HA, and Ramos cells or 1,000 particles per cell for CHO cells. After a 60-min incubation with the vector, the cells were washed twice and incubated for 16 to 20 h before being analyzed. The cells were lysed in 100 μl of 1× reporter lysis buffer and assayed for luciferase (Promega, Madison, Wis.).

Vector expression in vivo. For analysis of vector distribution following systemic delivery, 8- to 10-week-old female BALB/c mice (Charles River Laboratories, Wilmington, Mass.) were injected intraperitoneally with 10^11 particle units (PU) of vector in a volume of 100 μl. At 24 h postinjection the animals were sacrificed and tissues were collected and frozen immediately in liquid nitrogen. Direct injections were administered into the gastrocnemius muscle on each side of the mouse using 10^10 PU of vector in 50 μl per injection. Tissues were collected 24 h later, as for the systemic administrations. Lysates were prepared from ground tissues by extraction in 1× cell culture lysis reagent (Promega). The protein content of lysates was determined by the Bradford assay (Bio-Rad, Hercules, Calif.) using bovine serum albumin as a standard.

Southern blots. Viral DNA was isolated along with cellular genomic DNA by using DNeasy tissue kits (Qiagen, Valencia, Calif.). Tissue fragments were incubated overnight in proteinase K and then treated with RNase A. DNA was purified on minicolumns and quantitated by spectroscopy. Following digestion with KpnI, 5 μg of genomic DNA was loaded on a 0.8% agarose gel and

transferred to a Zeta-Probe membrane (Bio-Rad) following electrophoresis. The probe was labeled by random priming from a template containing the Ad5 pol region using [32P]dCTP and the Rediprime II DNA-labeling system (Amersham Pharmacia Biotech, Piscataway, N.J.). The probe was hybridized overnight in 5% sodium dodecyl sulfate (SDS)-0.5M Na2HPO4 (pH 7.2) at 65°C. The membrane was washed at 65°C in 40 mM Na2HPO4, 0.5% SDS followed by 40 mM Na2HPO4, 1% SDS. Bound probe was detected by autoradiography and was quantitated using an InstantImager (Packard Instrument Co., Meriden, Conn.).

PCR detection of vector sequences in tissue. Tissue DNA, isolated as described for Southern blots, was also analyzed by TaqMan PCR to detect vector DNA. Primers for amplification were located in the pX region with the sequences

GGGGTGTGACCTTAAATGAGGGGTGTGCTAACTC and GAGTTAGTACCCACCCCGAGCTTGGTCCTGTGTACC. The modified fiber was then isolated as a Xhol-MstI fragment and cloned into pGEM3Z(E3)10X, which carries an XhoI site at the 3′ end of the genome minus the XhoI fragment in E3. A Drfl fragment from this plasmid was used to construct the complete vector genome of AdL.F* by recombination in Escherichia coli.

Ad vectors modified to abolish native receptor interactions are depicted in Fig. 1. All express luciferase from a cytomegalovirus promoter in the E1 region. The fiber protein of AdL.F* carries amino acid substitutions within the AB loop which disable CAR binding, whereas AdL.PB* lacks the RGD motif within the penton base which binds αv integrins. An HA epitope was incorporated into the HI loop of the fiber protein of AdL.F* and in place of the penton base RGD in AdL.PB*. The fiber and penton base modifications, including the HA epitopes, were combined in AdL.PB*F*. Vector genomes were constructed by recombination in E. coli, and plasmids carrying the complete genomes of these vectors were transfected into 293 cells (AdL and AdL.PB* or 293-HA cells which express a membrane-anchored single-chain antibody capable of binding the HA epitope (AdL.F* and AdL.PB*F*). Expansion of the vectors in production runs using 2 × 10^9 to 1 × 10^10 cells infected at a multiplicity of infection of 20 PU showed comparable yields for the ablated and unmodified vectors (Table 1). The activities of AdL.F* and AdL.PB*F* were measured in focus-forming unit (FFU) assays on 293-HA cells. While AdL.F* exhibited PU/FFU ratios similar to those for AdL, AdL.PB*F* gave PU/FFU ratios about fourfold higher than those for AdL. This is consistent with the finding that luciferase expression from AdL.PB*F* is about 20% of the level detected from AdL following addition of equal particle numbers to 293-HA cells (data not shown).

The efficiency of gene transfer was analyzed by assaying luciferase expression in cells following incubation with Ad vectors. The effects of the vector modifications on transduction of AE25 cells are shown in Fig 2A. Whereas the addition of soluble fiber reduced AdL transduction by >70-fold, it had no effect on transduction by AdL.F*. This result is consistent with a model of transduction where the only role of fiber is to bind CAR. Interestingly, transduction by AdL.F* was reduced 12-fold in the presence of penton base protein, which had no effect on AdL transduction. Penton base affected AdL transduction only on combination with fiber, when a small additional reduction was seen. For AdL.PB*, only fiber inhibited transduction. The absence of additional penton base interactions for this vector is indicated by the lack of effect of penton base even when combined with fiber. Based on these results, a vector able to bind neither CAR nor αv integrins was con-
structed. This vector, designated AdL.PB*F* and also referred to as doubly ablated, transduced AE25 cells to a level nearly 3 orders of magnitude below what was seen with AdL. This residual transduction was less than 10-fold above the background measured in the absence of vector. Transduction by this vector was unaffected in the presence of either fiber or penton base or a combination of the two. Thus, it appeared that penton base inhibited transduction only when fiber was blocked from binding CAR and that this was mediated by the RGD motif. The significantly reduced transduction for the doubly ablated vector suggested that removal of the RGD motif could be critical for disabling the native transduction activity of Ad vectors in vivo.

On cells expressing a membrane-anchored single-chain antibody that binds to the HA peptide epitope incorporated in the coat proteins of the modified vectors, no significant differences were seen in transduction among the four vectors in the absence of competitors (Fig. 2B). Thus, the ability to bind cells via the anti-HA antibody overcomes the transduction deficiencies resulting from loss of CAR and αv integrins. Luciferase levels detected following infection with AdL in the presence or absence of competitors indicated no differences between AE25-HA and AE25 cells. On AE25-HA cells, unlike AE25 cells, AdL.F* exhibited no sensitivity to competition by penton base, presumably because the anti-HA–HA epitope interaction promotes binding, which masks this just as fiber-CAR binding does for AdL. AdL.PB*, on the other hand, remained very sensitive to competition by fiber protein on the AE25-HA cells. This suggested that the HA epitope inserted in place of the RGD motif in penton base was not effectively bound by the anti-HA protein. Transduction by AdL.PB*F* was dramatically increased on AE25-HA cells compared to that on AE25 cells. The results obtained with AE25-HA cells indicated that

| Vector    | No. of lots | Yield*  |
|-----------|-------------|---------|
|           | Pu/cell     | Pu/FFu  |
| AdL       | 10          | $2.57 \times 10^8 \pm 1.13 \times 10^8$ | $17.1 \pm 2.5$ |
| AdL.F*    | 5           | $1.51 \times 10^8 \pm 2.6 \times 10^8$ | $19.0 \pm 1.4$ |
| AdL.PB*   | 5           | $7.25 \times 10^8 \pm 3.1 \times 10^8$ | $24.9 \pm 7.1$ |
| AdL.PB*F* | 8           | $1.63 \times 10^8 \pm 5.8 \times 10^7$ | $68.6 \pm 13.7$ |

* Purified vector was analyzed by spectroscopy to determine the concentration in Pu, and the total yield was normalized to the starting number of cells used in the production run. FFU were determined in immunofluorescent-focus assays on 293 cells (AdL and AdL.PB*) or 293-HA cells (AdL.F* and AdL.PB*F*). The results are expressed as mean ± standard error.

FIG. 1. Schematic diagram of Ad vectors with altered cell surface interactions. AdL.F* has a modification in the AB loop of fiber (see Materials and Methods) that abolishes CAR binding and has an HA epitope inserted in the fiber HI loop. In AdL.PB*, the penton base RGD motif has been replaced by a HA epitope. AdL.PB*F* combines the modifications found in AdL.PB* and AdL.F*.

FIG. 2. Specificity of transduction of AE25 (A) and AE25-HA (B) cells by the panel of vectors. Cells were incubated with vector (50 Pu/cell) or medium alone (−) for 60 min, washed to remove vector, and incubated for 18 h before being harvested. Competitors (fiber at 5 μg/ml, penton base at 100 μg/ml, or a combination of the two) were incubated with the cells for 60 min before addition of the vector. Cell lysates were assayed for luciferase expression. rlu, relative light units. Symbols: ■ no competitor; ■, fiber; □, penton base; □, fiber plus penton base.
AdL.PB*F* caused a dramatic reduction of nearly 100-fold.

3-fold for the penton-modified vector AdL.PB*, but muscle by Ad vectors. Transduction of muscle was decreased does not play a prominent role in transduction of skeletal transduction to that due to AdL (Fig. 4), indicating that CAR integrins, respectively.

The activities of the panel of vectors in vivo were examined by direct intramuscular administration. Following injection into the gastrocnemius muscle, AdL.F* resulted in similar integrins (AdL.PB*F*) exhibited a drop in liver transduction of more than 700-fold compared to AdL. The reduced transduction by AdL.PB*F* was significantly lower than that by either AdL.F* (P < 0.03) or AdL.PB* (P < 0.03). The last two vectors exhibited decreases, respectively, of 10- and 20-fold versus AdL. Thus, the two modifications had a synergistic effect in reducing transduction of the liver. These results, together with the results from intramuscular injection, indicate that removing both the CAR and the αv integrin binding of Ad vectors is critical for reducing the native tropism of Ad vectors in vivo.

Additional tissues from these mice were analyzed for luciferase expression to examine the roles of CAR and αv integrin interactions. The level of transduction detected with AdL in all these tissues was ≤1% of that found in the liver. In the lung, heart, kidney, spleen, and muscle, abolishing CAR binding resulted in no reduction in transduction (Fig. 5). In fact, lung, kidney, and muscle transduction appeared elevated. In contrast to ablating CAR binding, ablating αv integrin binding alone reduced transduction in the lung, heart, and kidney (P < 0.05, P < 0.01, and P < 0.01, respectively), although transduction of muscle was not significantly different from that by AdL. The doubly ablated vector exhibited reduced transduction rel-
ative to AdL in the spleen (P = 0.02) as well as the lung, heart, kidney, and muscle (P < 0.01 for all). With the exception of the spleen, ablation integrin binding was more effective than abolishing CAR binding for limiting transduction. In lung, heart, and muscle, AdL.PB*F* resulted in significantly less transduction than did AdL.PB* (P < 0.02, P < 0.05, and P < 0.04, respectively), and in all five tissues the transduction measured for AdL.PB*F* was not significantly above background. We detected no difference among the vectors in the low level of transduction of the superficial inguinal node or the diaphragm (data not shown). In all tissues where transduction by AdL was detected, AdL.PB*F* gave reduced luciferase expression.

Southern blot analyses were performed on DNA isolated from individual tissues to examine vector distribution independent of expression. Clear differences were seen among the panel of vectors in terms of genomes detected in the liver (Fig. 6A). Quantitation of bound probe showed a two- to threefold decrease for AdL.F* versus AdL, regardless of whether the weakest AdL.F* sample was included above background. A 9-fold decrease relative to AdL was seen for AdL.PB*, while the vector signal was reduced by 13-fold for AdL.PB*F*. Thus, in terms of vector particles localizing to the liver, αv integrin binding had a greater impact than CAR binding. The synergistic effect on transduction of combining the CAR and integrin binding modifications was not observed at the level of localization of particles to the liver.

AdL DNA was localized primarily in the liver at 24 h post-administration. In the lung and heart, the AdL DNA level was at or below the level of detection (Fig. 6B and C). As reported above, expression in these tissues was less than 1% of that detected in the liver. A similar reduction in vector genomes would give a signal barely above background in the Southern blot analysis. Vector DNA was more readily detected in the spleen (Fig. 6D). In addition, a different pattern was seen for the panel of vectors in this tissue. There was no difference between the amounts of AdL.F* and AdL, while the amount of AdL.PB* was reduced about twofold. By contrast, the amount of AdL.PB*F* was increased nearly threefold versus AdL. Quantitation of bound probe indicated that the amount of AdL detected per 5 μg of splenic DNA was 8% of that detected with an equal quantity of liver DNA. Since the normal mouse liver is about nine times the size of the normal spleen in terms of weight, the fraction of the AdL dose present in the spleen was quite small compared to that in the liver. While the AdL.PB*F* level was elevated in the spleen relative to that of AdL and was also nearly threefold higher than that of AdL.PB*F* in the liver on a per-microgram-of-DNA basis, the size difference between the two organs indicates that the majority of this vector also localized to the liver.

We used real-time PCR analysis to further quantify differences in genome copies between the vectors within specific tissues. The results are presented as percentages of the numbers of copies detected for AdL in the respective tissue, since differences in PCR efficiency among organs limit a direct comparison of the number of vector copies detected in different tissues (Table 2). The number of relative copies detected for each vector in the liver by PCR agreed well with the Southern blot results. Abolition of CAR binding resulted in two- to threefold drop in the number of vector genomes detected. For AdL.PB*, the reduction was 10-fold relative to AdL and significantly reduced relative to AdL.F* (P < 0.03). The level of the doubly ablated vector was reduced 15-fold relative to that of AdL and was not significantly lower than that of AdL.PB*. PCR detection of the different vectors in the spleen also matched the results of Southern blotting, with AdL.PB*F* giving an elevation in the number of vector copies. We were able to detect vector DNA in the lung, heart, kidney, and diaphragm and found that loss of CAR binding did not result in a statistically significant reduction in the level of vector genomes in these tissues (Table 2). In contrast, AdL.PB* levels were significantly reduced relative to AdL levels in the lung (P < 0.01) and heart (P < 0.01), as were the levels of AdL.PB*F* (P < 0.01 for both). The levels of AdL.PB*F* were also significantly reduced relative to those of AdL in the diaphragm (P < 0.02) and relative to those of AdL.F* in the kidney (P < 0.04). Thus, the penton base modification had a broader effect than the fiber modification in reducing the number of vector copies in these tissues.

**DISCUSSION**

Using a panel of Ad vectors disabled for CAR binding, αv integrin binding, or both, we have found that ablating interac-
tions with both CAR and αv integrin is essential to significantly reduce the native tropism of an Ad vector. While fiber protein efficiently inhibited infection by the wild-type Ad vector in vitro, fiber modifications that abolish CAR binding resulted in a vector that was resistant to this inhibition. Therefore, there appeared to be no additional role of fiber in vector attachment. The vector that lacked CAR binding, however, exhibited sensitivity to inhibition by purified penton base that was not seen for the wild-type vector. This suggested that an interaction involving penton base could mediate transduction in the absence of fiber-CAR binding and prompted us to construct a vector ablated for both CAR and αv integrin binding. The significant reduction in transduction for the doubly ablated vector, AdLPB*F*, relative to the CAR-ablated vector, AdLPB*, indicated that an interaction between penton base and αv integrins was involved in the residual transduction by

![Image of Southern blot analysis](http://jvi.asm.org/)

**TABLE 2. Relative copies for the panel of vectors within specific tissues as detected by Taqman PCR**

| Tissue   | AdL   | AdLF*  | AdLPB* | AdLPB*F* |
|----------|-------|--------|--------|----------|
| Liver    | 100 ± 20 | 39 ± 11 | 10 ± 3.4 | 7.4 ± 1.7 |
| Spleen   | 100 ± 44 | 69 ± 13 | 41 ± 16 | 171 ± 36 |
| Lung     | 100 ± 24 | 103 ± 53 | 7.4 ± 4.8 | 14 ± 4.5 |
| Heart    | 100 ± 20 | 87 ± 30 | 9.3 ± 5.6 | 17 ± 6.6 |
| Kidney   | 100 ± 77 | 22 ± 8 | 7.4 ± 5.2 | 4.8 ± 0.5 |
| Diaphragm| 100 ± 41 | 82 ± 76 | 29 ± 18 | 8.8 ± 2.2 |

* Tissue DNA was analyzed using primers and probes that recognize the pIX region of Ad5. Results were obtained as the number of copies per nanogram of DNA.

* To control for tissue differences, the results are reported as percentages of the number of copies of AdL detected in the respective tissue following subtraction of background. The values listed are expressed as mean ± standard error.
AdL.F*. The inability of penton base protein to inhibit AdL.PB*F* transduction confirmed that the RGD loop of penton base was involved in the penton base-mediated transduction by AdL.F* and that additional interactions of penton base with cellular receptors were not involved in vector uptake.

The importance of abolishing both CAR and αv integrin binding for ablating native vector tropism was borne out by in vivo analysis. Following intravenous injection into mice, transgene expression from Ad was preferentially localized to the liver. Vectors unable to bind CAR caused a 10- to 20-fold reduction in transgene expression in the liver. This is consistent with what has been reported for Ad vectors complexed with neutralizing anti-fiber antibodies attached to targeting ligands (9, 17). Deleting only the RGD motif that mediates the αv integrin interaction, however, had as great an effect in reducing liver transduction as did loss of CAR binding. However, the most dramatic result was the drop in liver transduction measured with the doubly ablated vector. The fiber and penton base modifications had a synergistic effect, resulting in a >700-fold decrease of luciferase expression in the liver. The residual transduction resulted in expression that was within 1 log unit of that seen in mock-treated animals.

The penton base-αv integrin interaction has been proposed to be important for efficient internalization of Ad from the cell surface via receptor-mediated endocytosis, and this interaction may also be important for cell signaling and for release of vector cores from the endosome (reviewed in reference 14). Based on these observations, one might expect that the impact of the penton base RGD mutation on in vivo transduction is inefficient internalization. This would suggest that at least part of the reduced expression from the doubly ablated vector resulted from loss of transduction activity of the particles rather than from targeting. If this were the case, employing the doubly ablated vector as a base for targeted vectors might require, for example, selecting target receptors that could mediate endocytosis of the vector. While differences in receptor internalization may influence the relative effectiveness of retargeting the doubly ablated vector to specific novel receptors, our results suggest that the consequences of the RGD deletion in reducing transduction could take effect prior to internalization. First, no difference in transduction activity among the unmodified, the CAR-ablated, the integrin-ablated, and the doubly ablated vectors was detected on AE25-HA cells. It appears that under these conditions, attachment via the anti-HA receptor or CAR is sufficient for efficient internalization. Second, the RGD deletion caused a marked reduction in the level of vector genomes detected in a number of tissues. Unless the Southern and PCR analyses preferentially detected internalized genomes, these results point to an influence of the RGD deletion on vector distribution rather than just to vector internalization.

Expression data from experiments with additional tissues besides the liver underscored the importance of deleting the penton base RGD motif for altering Ad tropism. No significant decrease in transduction was seen in the lung, heart, kidney, spleen, or skeletal muscle for the CAR-ablated vector, AdL.F*. Following intravenous injection, AdL.F* gave elevated expression in skeletal muscle and some evidence for elevated expression in the lung and kidney. Expression from AdL.PB*, on the other hand, was significantly reduced relative to that from AdL in the lung, heart, and kidney. In the spleen, a combination of the penton base and fiber modifications was necessary to reduce expression.

Both AdL.F* and AdL.PB* showed a decrease in the number of vector genomes in the liver by Southern blot analysis, but the penton base modification had a greater effect. With the possible exception of the kidney, Taqman PCR detected no significant decrease in the numbers of AdL.F* genomes in tissues other than the liver. In contrast, the numbers of AdL.PB* genomes were reduced in the lung, heart, kidney, spleen and diaphragm. The reduction of the numbers of AdL.PB* genomes was similar to that of the numbers of AdL.PB*F* genomes, except in the spleen, where the AdL.PB*F* level was elevated relative to that of AdL. These results indicate not only that interactions other than those with the fiber receptor can influence vector distribution but also that in most tissues the penton base interaction has more influence than binding of CAR by fiber.

In the liver, both AdL.PB* and AdL.PB*F* showed a reduction in vector copies of about 10-fold, but whereas AdL.PB* expression was decreased about 20-fold relative to that of AdL, the reduction of AdL.PB*F* expression was 7000-fold. The magnitude of the decrease in expression of AdL.PB*F* greatly exceeds the reduction in the number of detectable genomes. In AdL.F*, we detected a 2- to 3-fold drop in the number of vector copies together with a 10- to 20-fold drop in expression. The greater effect on expression of the CAR-ablating modification in the context of the RGD deletion suggests that the penton base can mediate transduction in the liver, just as we observed in vitro. It is likely that there are multiple mechanisms causing localization of Ad vectors to the liver, and future studies are needed to analyze the specific types of cells in the liver that take up vector.

The data reported here were collected from tissues harvested at 24 h after vector administration. DNA analysis has indicated that as much as 90% of an intravenous dose of Ad vector disappears within the first 24 h via clearance and degradation in the liver (30). When circulation through the liver was bypassed, systemic administration of Ad to mice resulted in persistence of the vector in the circulation and enhanced transduction of the lung, kidney, and intestine (31). Kupffer cells appear to play a role in clearance by the liver, but the precise mechanism has not been elucidated (1, 12, 21, 29). The increase in the vector DNA level detected in the spleen for AdL.PB*F* could reflect altered vector circulation in the absence of CAR and integrin binding. The magnitude of the increase seen for AdL.PB*F* DNA in the spleen, however, was insufficient to account for the decrease of AdL.PB*F* DNA in other tissues and does not indicate any increase in the total amount of vector DNA detected at 24 h. Based on these results, it appears that absence of CAR and αv integrin binding does not enable an Ad vector to escape rapid clearance and degradation following intravenous administration.

The enhanced transduction in lung, kidney, and skeletal muscle that we detected for AdL.F* and the increased levels of AdL.PB*F* in the spleen provide evidence that altering the interactions of Ad vectors with CAR and αv integrin can alter their distribution in vivo. Given the similar levels of expression from AdL and AdL.F* following direct intramuscular injection, the greater expression from AdL.F* following systemic administration appears to reflect a difference in distribution of
the two vectors. At the same time, interactions beyond those with CAR and αv integrins affect the fate of Ad vectors following systemic delivery (7, 31). While access to specific target tissues can be limited by physical barriers (5, 13, 25), the rapid clearance of Ad vectors in the liver impacts any application where a vector might be administered systemically. The vectors we evaluated have ablated receptor specificity. While limiting the interaction of Ad vectors with native receptors is critical for development of vectors that have greater specificity for target tissues, the efficacy of novel receptor specificities incorporated in the doubly ablated vector remains to be tested.

Since the liver is the major site of transcgene expression following intravenous administration of Ad vectors in mice, the dramatic reduction in transduction of this organ by the doubly ablated vector represents a significant finding for developing targeted Ad vectors. The reduced levels of this vector in most tissues examined should enhance the targeting specificity of the vector carrying novel targeting sequences. Targeting of phage particles to specific tissues has been demonstrated in vivo through the incorporation of short linear peptide motifs (2, 15). Targeted Ad vectors could be developed by incorporating these ligands (23), or Ad vectors might be used directly to identify ligands. Vectors with ablated tropism, through loss of CAR and αv integrin binding, provide an improved platform for evaluating the targeting potential of peptide ligands incorporated in Ad capsids. Further modifications of the vector to avoid rapid clearance from the circulation might result in even greater targeting efficiency, as well as in advantages from enabling therapeutic efficacy at lower vector doses.

REFERENCES

1. Alemany, R., K. Suzuki, and D. T. Curiel. 2000. Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 81:2605–2609.
2. Arap, W., R. Pasqualini, and E. Ruoslahti. 1998. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:377–380.
3. Bai, M., B. Harfe, and P. Freemuth. 1993. Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-binding activity and delay virus reproduction in flat cells. J. Virol. 67:5198–5205.
4. Bergelson, J. M., A. Krithivas, L. Celi, G. Droguett, M. S. Horwitz, T. Wickham, R. L. Crowell, and R. W. Finberg. 1998. The murine CAR homolog is a receptor for caskic B viruses and adenoviruses. J. Virol. 72:415–419.
5. Cho, W. K., S. Ebihara, J. Nalbantoglu, R. Gilbert, B. Massie, P. Holland, G. Karpati, and B. J. Petrof. 2000. Modulation of Starling forces and muscle fiber maturity permits adenovirus-mediated gene transfer to adult dystrophic (mdx) mice by the intravascular route. Hum. Gene Ther. 11:701–714.
6. Einfeld, D. A., D. E. Brough, P. W. Roelvink, I. Kovesdi, and T. J. Wickham. 1999. Construction of a pseudoreceptor that mediates transduction by adenovirus expressing a ligand in fiber or penton base. J. Virol. 73:9130–9136.
7. Fechner, H., A. Haack, H. Wang, X. Wang, K. Eizema, M. Pauschinger, R. Schoemaker, R. Vehgel, A. Houtsmuller, H. P. Schultheiss, J. Lamers, and E. Falck-Pedersen. 1999. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 286:1568–1571.
8. Luber, A., C. Y. He, L. Meuse, D. Schowalter, I. Kirillova, B. Winther, and J. D. Mountz. 1999. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 10:1015–1022.
9. Reynolds, P. N., K. R. Zinn, V. T. Gavrilyuk, I. V. Baliyskina, B. E. Rogers, J. D. Buchsbaum, M. H. Wang, D. J. Miletich, E. W. Grizzle, J. L. Walters, S. M. Danilov, and D. T. Curiel. 2000. A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol. Ther. 2:562–578.
10. Roelvink, P. W., I. Kovesdi, and T. J. Wickham. 1996. Comparative analysis of adenovirus fiber-cell interactions: adenovirus type 2 (Ad2) and Ad9 utilize the same cellular fiber receptor but use different binding strategies for attachment. J. Virol. 70:7614–7621.
11. Tomko, R. P., R. Xu, and L. Philipson. 1997. CAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B caskicaseviruses. Proc. Natl. Acad. Sci. USA 94:3352–3356.
12. Trepel, M., M. Grifman, M. D. Weitzman, and R. Pasqualini. 2000. Molecular adaptors for vascular-targeted adenoviral gene delivery. Hum. Gene Ther. 11:1971–1981.
13. Worgall, S., G. Wolff, E. Falck-Pedersen, and R. G. Crystal. 1999. Imaging and tissue biodistribution of 99mTc-labeled adenovirus knob (serotype 5). Gene Ther. 6:2363–2367.
14. Dimitrov, D. S., Y. Zhu, and A. H. Goldfarb. 1998. A targetable, injectable adenovirus vector for selective gene delivery to pulmonary endothelium in vivo. Mol. Ther. 2:562–578.
15. Nemerow, G. R., and P. L. Stewart. 1999. Role of alpha(v) integrins in adenovirus cell entry and gene delivery. Microbiol. Mol. Biol. Rev. 63:725–734.
16. Pasqualini, R. 1999. Vascular targeting with phage peptide phages. Q. J. Nucl. Med. 43:159–162.
17. Pickles, R. J., D. McCarty, H. Matsui, P. J. Hart, S. H. Randell, and R. C. Boucher. 1998. Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer. J. Virol. 72:6014–6023.
18. Tomko, R. P., R. Xu, and L. Philipson. 1997. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B caskicaseviruses. Proc. Natl. Acad. Sci. USA 94:3352–3356.
19. Trepel, M., M. Grifman, M. D. Weitzman, and R. Pasqualini. 2000. Molecular adaptors for vascular-targeted adenoviral gene delivery. Hum. Gene Ther. 11:1971–1981.
20. Worgall, S., G. Wolff, E. Falck-Pedersen, and R. G. Crystal. 1997. Enhancement of in vivo adenovirus-mediated gene transfer but not virus attachment. Cell 82:279–289.
21. Worgall, S., G. Wolff, E. Falck-Pedersen, and R. G. Crystal. 1999. Enhancement of in vivo adenovirus-mediated gene transfer by high affinity fiber receptor binding. J. Virol. 73:1822–1829.
22. Zinn, K. R., J. T. Douglas, C. A. Smyth, H. G. Liu, Q. Wu, V. N. Krasnykh, D. T. Curiel, and J. M. Mountz. 1998. Imaging and tissue biodistribution of 99mTc-labeled adenovirus knob (serotype 5). Gene Ther. 5:798–808.